Abstract: The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI).

Abstract: The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (C1-INH), exhibiting a higher stability for prolonged storage and a reduced formation of aggregates of said esterase inhibitor (C1-INH) upon storage for ameliorated use in treating or preventing disorders related to kinin formation.

Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl

Abstract: The present invention relates to a process for purifying C1-esterase inhibitor (C1-INH), and more in particular a C1-INH concentrate.

Abstract: The present invention relates to a method of filtrating a solution comprising von Willebrand Factor (VWF), the method comprising (a) providing a solution comprising VWF and a basic amino acid; and (b) subjecting the solution of step (a) to a virus filtration through a filter having a pore size of less than or equal to 35 nm.

Abstract: Methods are disclosed for treating cerebral ischemia using a combination of C1-INH and immunoglobulin, such as human plasma derived immunoglobulin (IVIG).

Abstract: The present invention relates to a therapeutic agent for amniotic fluid embolism (AFE). Furthermore, the present invention relates to a therapeutic agent for AFE comprising a C1-inhibitor, particularly a human plasma-derived C1-inhibitor.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasm

Abstract: The invention relates to the use of Factor H for the manufacture of a medicament to treat both chronic nephropathies which are not causally associated with proteinuria and chronic nephropathies which are causally associated with proteinuria. The invention also relates to large scale purification methods for Factor H.

Abstract: The present invention pertains to a pharmaceutical product comprising a polyclonal immunoglobulin solution in a pre-filled polymer syringe in secondary packaging comprising an oxygen scavenger.

Abstract: The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (“C1-INH”), exhibiting a higher stability for prolonged storage and a reduced kinematic viscosity for ameliorated use in treating or preventing disorders related to kinin formation.

Abstract: A workpiece clamping device for a machine tool is provided, which has a base, first and second clamping jaws between which a workpiece is clampable, a drive, and an actuating element which is displaceable relative to the base and which is coupled to the first clamping jaw. A movement of the actuating element is brought about by the drive and the actuating element brings about a displacement of the first clamping jaw. A transmitter is arranged on the actuating element and is displaceable together with the actuating element and is displaceable relative to the actuating element. A first stop and a spaced-apart second stop are provided, between which stops the transmitter is displaceable together with the actuating element. When the transmitter abuts against the first or second stop, the transmitter is displaceable relative to the actuating element. A sensor is provided for detecting one or more positions of the transmitter.

Abstract: The present invention relates to pharmaceutical preparations comprising two-chain Factor VIII that are essentially free of Factor VIII-Light Chains (FVIII-LCs) which are not associated with Factor VIII-Heavy Chains (FVIII-HCs) having higher purity and which are less immunogenic. The invention also relates to methods to test the suitability of a pharmaceutical Factor VIII preparation and to methods to reduce in pharmaceutical Factor VIII preparations the amount of FVIII-HCs which are not associated with FVIII-LCs and/or of FVIII-LCs which are not associated with FVIII-HCs.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI).

Abstract: In order to improve a saw device with a feed axis for a workpiece to be sawed, with a first saw unit to saw the workpiece in a first sawing plane extending transversely to the feed axis and with a second saw unit to saw the workpiece in a second sawing plane extending transversely to the feed axis, with a central device region arranged between the sawing planes, with a front device region arranged in front of the first sawing plane, viewed in a feed direction, and with a rear device region arranged behind the second sawing plane, viewed in the feed direction, in such a way that as high a cutting efficiency as possible can be achieved, it is proposed that the saw device comprises at least two transport mechanisms arranged in different device regions to transport different workpiece portions along the feed axis.

Abstract: The present invention relates to a holder for an injection syringe (18), with a housing (12) designed to receive the syringe, with a stand (14) for placing on a supporting surface, and with retaining means (38, 52, 54, 62, 64) for axially and/or radially fixing the syringe (18) on or in the holder, wherein the retaining means (38, 52, 54, 62, 64) are designed in such a way that an outlet (26) of a syringe (18) arranged vertically in the holder comes to lie facing the free end of the stand (14) and at a distance therefrom.

Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.

Abstract: The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.